SBIR/STTR Research Award

High-specificity affinity reagents for the detection of glycan sialylation

Award identifier 4e087cc3cc44ff7579c4d897445be3c8e5061a2c5660a8ab9dec8809c5bb3cf1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,049,907

Program and phase

SBIR · Phase II

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LECTENZ BIO, INC.
Proposal award date
2018-01-15
Contract end date
2020-12-31
UEI
JTGCK219C6F4
Solicitation number
PA16-157
Topic code
300

Research abstract

PROJECT SUMMARY Glycans have several distinct properties that make them potential disease biomarkers. Firstly, their location on cell surfaces makes them the first point of contact for cellular interactions, and thus they are crucial in the control of normal metabolic processes. Secondly, cell surface molecules are strategically exposed for surveillance by the immune system, where they may serve as immune recognition elements. Thirdly, specific glycan structures that are not present, or are in low amounts in normal states, proliferate in disease states, such as cancer. For example, variation in glycan sialylation is a marker for diseases, such as rheumatoid arthritis and prostate cancer, however, to fully exploit sialic acid as a disease marker requires the ability to detect it in each of its linkage contexts. At present multiple lectins are employed in serial lectin affinity chromatography to enrich sialylated glycans for glycomic analysis, which because of specificity issues associated with the lectins risks capturing irrelevant non-sialylated components. To overcome the limitations of existing lectins, we have used structurally-guided mutagenesis, to convert the carbohydrate-processing enzyme NanB (from S. pneumoniae) into a high-affinity reagent (Sia-3S1) specific for detecting 3andapos;-sialylated glycans. Sia-3S1 shows significant advantages over existing reagents in chromatographic applications that are commonly used in disease marker detection. Such engineered proteins are referred to as “Lectenz®” because they have lectin-like properties, but retain the specificity of the endogenous enzymes. Lectenz® have several advantages over either lectins or antibodies, including precise definition of specificity, tuneable affinity, and ease of production. Few reagents exist that can be used to enrich a sample for unique glycan modifications. Specific Lectenz® such as Sia-3S1 directly address the needs of glyco-biomarker detection and mass spectrometry-based glycomics/proteomics analysis by enabling or improving sample enrichment. It could also be employed in histological studies, or Western blots, etc. In this application we illustrate that the development of Sia-3S1 has passed the proto-type stage, and demonstrate the scientific and technical merit and feasibility of advancing this technology into a highly desirable reagent and commercializable suite of tools.PROJECT NARRATIVE Currently, there is a need for robust, high-specificity reagents to study the structure and function of glycans. Using structurally-guided genetic manipulations, we are converting carbohydrate-processing enzymes into a high-specificity affinity reagents (called Lectenz®) for the detection of important, often disease-related, glycan modifications. Here we illustrate that the development of one such reagent (Sia-3S1) has passed the proto- type stage, and demonstrate the scientific and technical merit and feasibility of advancing this technology into a highly desirable reagent and commercializable suite of tools.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

18 SBIR/STTR records share this UEI (2009–2025). Reported award amounts total $14,474,759. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.